Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. by Failli, Paola et al.
Nitrovasodilators Inhibit Platelet-Derived Growth
Factor–Induced Proliferation and Migration of Activated
Human Hepatic Stellate Cells
PAOLA FAILLI,* RAFFAELLA M. S. DEFRANCO,‡ ALESSANDRA CALIGIURI,‡
ALESSANDRA GENTILINI,‡ ROBERTO GIULIO ROMANELLI,‡ FABIO MARRA,‡ GIACOMO BATIGNANI,§
CRISTINA TOSTI GUERRA,‡ GIACOMO LAFFI,‡ PAOLO GENTILINI,‡ and MASSIMO PINZANI‡
*Dipartimento di Farmacologia Preclinica e Clinica, ‡Dipartimento di Medicina Interna, Firenze; and §Dipartimento di Fisiopatologia
Clinica-Unita` di Chirurgia, Universita` di Firenze, Firenze, Italy
Background & Aims: Nitrovasodilators have been pro-
posed for the treatment of portal hypertension alone
or in combination with b-blockers. In addition to their
vasodilatory properties, nitric oxide (NO) donors may
exert direct antifibrogenic properties. We evaluated
the effect of nitroglycerin (NTG) and S-nitroso-N-acetyl
penicillamine (SNAP) on the mitogenic and chemotac-
tic properties of platelet-derived growth factor (PDGF)-
BB and the modulation of the relative intracellular
signaling pathways in fully activated human hepatic
stellate cells (HSCs), a cell type that plays an active
role in liver fibrogenesis and portal hypertension.
Methods & Results: Both NTG and SNAP induced a dose-
dependent decrease in PDGF-induced DNA synthesis
and cell migration, which was associated with a de-
crease in PDGF-induced intracellular Ca21 increase and
extracellular signal-regulated kinase (ERK) activity.
These effects were not related to activation of the clas-
sic soluble guanylate cyclase (sGC)/guanosine 3*,5*-cy-
clic monophosphate pathway; accordingly, Western blot
analysis of HSC lysates revealed the absence of the
a1b1 ubiquitous subunits of sGC, whereas they were
detectable in quiescent HSCs, freshly isolated from nor-
mal human liver. Conversely, both NTG and SNAP in-
duced a more than 10–20-fold increase in prostaglandin
E2 in cell supernatants within 1 minute, associated with
an increase in intracellular adenosine 3*,5*-cyclic mono-
phosphate levels. Accordingly, the inhibitory effects of
NO donors on PDGF action and signaling were elimi-
nated after preincubation with ibuprofen. Conclusions:
These results suggest that NO donors may exert a direct
antifibrogenic action by inhibiting proliferation, motility,
and contractility of HSCs in addition to a reduction of
fibrillar extracellular matrix accumulation.
Experimental and clinical studies have indicated thatshort-term and long-term administration of different
nitrovasodilators may reduce portal pressure.1–3 Accord-
ingly, these compounds, particularly isosorbide-5-mono-
nitrate, have been proposed for the treatment of portal
hypertension alone or in combination with b-blockers,4,5
although their use may be contraindicated in patients
with cirrhosis with ascites.6
The direct action of organic nitrates on the intrahe-
patic circulation, although well conceivable according to
the constitutive vasodilatory properties of these com-
pounds, has not been substantiated in cellular and mo-
lecular terms.
A close relationship occurs between the progression of
liver fibrosis and development of portal hypertension.
Particularly, development of portal-central anastomoses
and arterialization/capillarization of sinusoids represent
hallmarks of the fibrogenic process as well as key deter-
minants for the increase in intrahepatic vascular resis-
tance.7 Indeed, portal-central anastomoses, although
representing direct connections between the portal and
systemic circulation, follow irregular patterns and are
embedded in developing scar tissue where a complex
interplay between several cell types and soluble media-
tors occurs. In this context, several in vitro and in vivo
studies have highlighted the role of activated hepatic
stellate cells (HSCs),8–10 a cell type primarily involved in
the development of liver fibrosis.11,12 In their activated
phenotype, stellate cells are characterized by remarkable
proliferative, chemotactic, and contractile properties.
Particularly, contraction of activated HSCs in response to
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different vasoconstrictors, including endothelin 1 and
thrombin,8,13,14 has been suggested to play an important
role in the contraction of developing scar tissue, and, con-
sequently, in the progression of portal hypertension. HSC
contraction is counterbalanced by vasorelaxing agents such
as nitric oxide (NO),15 which has been proposed as a regu-
lator of sinusoidal blood flow in the normal liver.16 Along
these lines, in vitro and in vivo evidence indicates that
sinusoidal endothelial cells express constitutive NO syn-
thase and produce NO, and increase their production in
response to flow.17 However, an endothelial dysfunction
associated with decreased production of NO in the intrahe-
patic microcirculation has been extensively documented in
the cirrhotic liver,18,19 and these defects could directly con-
tribute to the increased intrahepatic resistance typical of
portal hypertension.20 These observations provide per se a
sound rationale for the use of nitrovasodilators in the treat-
ment of portal hypertension.
Expression of platelet-derived growth factor (PDGF),
a key mitogen and chemoattractant for HSCs21,22 and of
the relative receptor subunits, is markedly up-regulated
in human fibrotic liver and correlates with the extent of
necroinflammatory and fibrogenic activity.23 Further-
more, expression of PDGF receptors is a consistent fea-
ture of the process of HSC activation in vitro and in
vivo.21,23 NO donors have been shown to reduce collagen
type I deposition in vascular smooth muscle cells and in
human HSCs,24,25 and NO release induced by proinflam-
matory cytokines has been proven responsible for the
inhibition of a–smooth muscle actin expression, a
marker of HSC activation.26 In addition, a possible direct
antifibrogenic effect of NO donors is suggested by in
vitro studies showing antiproliferative and antichemo-
tactic actions of these compounds in vascular smooth
muscle cells and glomerular mesangial cells.27–30 How-
ever, the possible cellular and molecular mechanisms
responsible for the action of NO donors in this setting
have not been clarified.
Because of the close link between the progression of
liver fibrosis and the development of portal hypertension,
we evaluated the effects of two NO donors, nitroglycerin
(NTG) and S-nitroso-N-acetyl penicillamine (SNAP), on
the biological actions and the intracellular signaling of
PDGF in activated human HSCs.
Materials and Methods
Reagents
Monoclonal antiphosphotyrosine antibodies for West-
ern blotting were purchased from UBI (Lake Placid, NY).
Polyclonal antibodies against extracellular signal–regulated
kinase (ERK)-1 and phospholipase Cg1 (PLCg) were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). Poly-
clonal antibodies against soluble guanylate cyclase (sGC) (a1b1
heterodimeric form) were purchased from Alexis Corp. (San
Diego, CA). Myelin basic protein was purchased from Sigma
Chemical Co. (St. Louis, MO), and protein A–Sepharose from
Pharmacia (Uppsala, Sweden). [g-32P]adenosine triphosphate
(ATP) (3000 Ci/mmol), [a-32P]deoxycytidine triphosphate
(3000 Ci/mmol), and [methyl-3H]thymidine (6.7 Ci/mmol)
were from New England Nuclear (Milan, Italy). Human re-
combinant PDGF-BB was purchased from Peprotech (Rock
Hill, NJ), and human thrombin from Boehringer Mannheim
GmbH (Mannheim, Germany). SNAP was purchased from
Tocris Cookson Ltd. (Bristol, England); LY-83583 and
KT5823 from Calbiochem Corp. (San Diego, CA); and Fura-
2-acetyloxymethylester purchased from Molecular Probes (Eu-
gene, OR). A working solution of NTG was obtained by
diluting a commercially available preparation for intravenous
infusion (Venitrin; Astra, Milan, Italy) with sterile water. All
other reagents were of analytical grade.
Isolation and Culture of Human HSCs
Human HSCs were isolated from wedge sections of nor-
mal human liver unsuitable for transplantation, as reported pre-
viously.8,31 Briefly, after a combined digestion with collagenase/
pronase, HSCs were separated from other liver nonparenchymal
cells by ultracentrifugation over gradients of stractan (Cellsep
isotonic solution; Larex Inc., St. Paul, MN). Extensive character-
ization was performed as described previously.31 Cells were cul-
tured on plastic culture dishes (Falcon; Becton Dickinson, Lincoln
Park, NJ) in Iscove’s modified Dulbecco’s medium supplemented
with 0.6 U/mL insulin, 2.0 mmol/L glutamine, 0.1 mmol/L
nonessential amino acids, 1.0 mmol/L sodium pyruvate, antibiotic
antifungal solution (all provided by GIBCO Laboratories, Grand
Island, NY), and 20% fetal bovine serum (FBS) (Imperial Labo-
ratories, Andover, England). Experiments described in this study
were performed on cells between the third and fifth serial passages
(1:3 split ratio) using 3 independent cell lines. As already report-
ed,31 at these stages of culture, human HSCs showed transmission
electron-microscopic features of myofibroblast-like cells, thus in-
dicating complete transition to their activated phenotype. In
experiments using freshly isolated human HSCs, an aliquot of the
cell isolate was immediately used for guanosine 39,59-cyclic
monophosphate (cGMP) determinations or frozen for protein
analysis, whereas the remaining aliquot was cultured as specified
earlier.
DNA Synthesis
DNA synthesis was measured as the amount of [methyl-
3H]thymidine ([3H]TdR) incorporated into trichloroacetic
acid–precipitable material. Cells were plated in 24-well dishes
at a density of 2 3 104 cells/well in complete culture medium
containing 20% FBS. Confluent cells (approximately 1 3 105
cells/well) were made quiescent by incubation in serum-free/
insulin-free (SFIF) medium for 48 hours. Unless otherwise
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specified, cells were incubated with or without agonists at the
indicated doses and modalities for 20 hours and then pulsed for
an additional 4 hours with 1.0 mCi/mL [3H]TdR. At the end
of the pulsing period, [3H]TdR incorporation into cellular
DNA was measured as previously reported.21 Cell number was
determined in 3 separate wells from each dish; results are
expressed as counts per minute per 105 cells.
Cell Growth Assay
Human HSCs were plated in 12-well dishes at a den-
sity of 6 3 104 cells/well in complete culture medium. After
24 hours cells were washed twice with SFIF medium and
placed in the same medium containing PDGF-BB (10 ng/mL)
with or without NO donors (day 0). Cell counts were per-
formed on triplicate wells at day 0, 2, and 4 by trypsinizing
the cells and using a Coulter counter (Coulter Electronics Inc.,
Hialeah, FL). Fresh SFIF medium containing PDGF-BB with
or without NO donors at the same concentrations was added to
the remaining wells at day 2. Results are expressed as the
absolute cell number at each day of observation.
Chemotactic Assay
Cell migration was performed as described previ-
ously.22,32 Briefly, the experiments were performed using a
modified Boyden chamber technique equipped with 8-mm-
pore polyvinylpyrrolidone-free polycarbonate filters (13-mm
diameter). Polycarbonate filters were precoated with 20 mg/mL
of human type I collagen for 30 minutes at 37°C and placed
between the upper and the bottom chamber. Confluent HSCs
in 6-well dishes were incubated in SFIF medium for 48 hours
and then treated with increasing concentrations of NO donors
for 10 minutes. They were then suspended by mild trypsiniza-
tion (0.05% trypsin/EDTA), and an aliquot (210 mL) of the
obtained cell suspension, corresponding to 4 3 104 cells, was
added to the top well and incubated at 37°C for 6 hours. The
lower chamber was filled with SFIF medium (control) or
PDGF-BB (10 ng/mL) in the presence or absence of the same
concentration of NO donors used in the preincubation. After
fixing in 96% methanol and staining with Harris’ hematoxylin
solution, cells migrated to the underside of the filters and were
quantified as the mean number of cells in 10 high-power fields.
All experiments were performed in triplicate. Each triplicate
assay was repeated 2 times on separate occasions with different
HSC preparations. Possible cytotoxic effects were monitored
by the trypan blue exclusion test.
ERK Assay
ERK was measured as the myelin basic protein kinase
activity of ERK immunoprecipitates. The cell monolayer was
lysed in RIPA (radioimmunoprecipitation assay) buffer (20
mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 5 mmol/L
EDTA, 1% Nonidet P-40, 1 mmol/L Na3VO4, 1 mmol/L
phenylmethylsulfonyl fluoride, and 0.05% [wt/vol] aprotinin).
Insoluble proteins were discarded by high-speed centrifugation
at 4°C. Protein concentration in the supernatant was measured
in triplicate using a commercially available assay (Bio-Rad,
Hercules, CA). Fifty micrograms of total cell lysate was im-
munoprecipitated with anti–ERK-1 antibodies and protein
A–Sepharose. Measurement of ERK activity was performed as
described previously.33 Sodium dodecyl sulfate–polyacrylam-
ide gel electrophoresis (SDS-PAGE) and Western blotting
were performed using previously described techniques.22
Digital Video Imaging of Intracellular-Free
Calcium Concentration in Individual
Human HSCs
Digital video imaging of intracellular-free calcium
concentration ([Ca21]i) in individual human HSCs was per-
formed as described previously.8,34 Human HSCs were grown
to subconfluence in complete culture medium on round glass
cover slips (25-mm diameter, 0.2-mm thick) for 72 hours, and
then incubated for 48 hours in SFIF medium. Cells were then
loaded with 10 mmol/L Fura-2AM and 15% Pluronic F-127
for 30 minutes at 22°C. [Ca21]i was measured in Fura-2–
loaded cells in HEPES-NaHCO3 buffer containing 140
mmol/L NaCl, 3 mmol/L KCl, 0.5 mmol/L NaH2PO4, 12
mmol/L NaHCO3, 1.2 mmol/L MgCl2, 1.0 mmol/L CaCl2, 10
mmol/L HEPES, and 10 mmol/L glucose, pH 7.4. Ratio
images (340/380 nm) were collected every 3 seconds, and
calibration curves were obtained for each cell preparation.34
PDGF-BB (10 ng/mL) or thrombin (0.3 U/mL) was added
directly to the perfusion chamber immediately after recording
the [Ca21]i basal value. In parallel experiments, cells were
preincubated with NO donors 10 minutes before the addition
of PDGF-BB or thrombin. In experiments evaluating changes
in cell area induced by thrombin, spatial calibration was
performed by measuring division on a graticule under the same
optical conditions as the rest of the experiments, as reported.8
Northern Blot Analysis
RNA was isolated according to Chomczynski and
Sacchi.35 Total RNA (10 mg) was fractionated by 1% agarose-
formaldehyde gel electrophoresis and blotted on a nylon
membrane. Procedures for DNA radiolabeling and filter
hybridization have been described.36
Assay of Intracellular cGMP Levels
Confluent HSCs in 35-mm well dishes were incubated
in SFIF medium for 48 hours. This medium was replaced with
SFIF containing 100 mmol/L 3-isobutyl-1-methyl-xanthine
(IBMX). Cells were incubated for 10 minutes with 10 ng/mL
PDGF-BB, 10 and 100 mmol/L NTG, or 10 or 100 mmol/L
SNAP. The reaction was stopped by the addition of 500 mL of
20% ice-cold HClO4, and dishes were placed on a shaker at
4°C for 20 minutes. Samples were collected, neutralized at pH
7.5 by adding 1.08 mol/L K3PO4, and kept at 4°C overnight.
After centrifugation at 6000 rpm at 4°C for 10 minutes,
supernatants were collected and lyophilized. In experiments
using freshly isolated human HSCs, cells were divided in
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aliquots of 5 3 105/tube and resuspended in 1 mL of SFIF
medium containing 100 mmol/L IBMX. After 10 minutes of
incubation at 37°C, cells were stimulated with NTG or SNAP
(both at a concentration of 100 mmol/L) for 10 minutes. The
reaction was then terminated as indicated earlier. cGMP levels
were measured by Cyclic GMP [3H] Assay System (Amersham
Pharmacia Biotech UK Ltd., Little Chalfont, England) accord-
ing to the manufacturer’s instructions. Cell number was de-
termined in 3 separate wells from each dish after trypsinization
and counting. Time course experiments were performed to
monitor cGMP synthesis at 5, 10, 15, and 30 minutes after
addition of the agonists.
Assay of Intracellular cAMP Levels
Confluent HSCs in 22-mm well dishes were incubated
in SFIF medium for 48 hours. This medium was then removed
and replaced with 200 mL/well of a buffer containing 0.025
mol/L Tris-HCl, 0.25 mol/L sucrose, 0.5% bovine serum
albumin, and 100 mmol/L IBMX, pH 7.4. Agonists were
added to the wells, and the cells were incubated at 37°C for 10
minutes. The reaction was stopped by the addition of 500 mL
of 100% ice-cold ethanol, and dishes were placed at 220°C for
at least 24 hours. Samples were then centrifuged at 2500g at
4°C for 20 minutes, and supernatants were collected, lyophi-
lized, and reconstituted with 50 mmol/L sodium acetate
buffer, pH 6.2. Intracellular adenosine 39,59-cyclic monophos-
phate (cAMP) levels were measured by the cAMP [125I] assay
system (Amersham Pharmacia Biotech UK Ltd.) according to
the manufacturer’s instructions. Cell number was determined
in 3 separate wells from each dish after trypsinization and
counting.
Preparation of Human Platelets
Blood from healthy volunteers who had not taken
drugs for at least 10 days was collected by venipuncture and
immediately diluted 1/5 with citric acid/trisodium citrate/
glucose (1.5%:2.5%:2%, wt/vol). Platelet-rich plasma was
prepared by centrifugation at 180g at 20°C for 15 minutes.
Platelets were washed twice and collected by centrifugation as
described previously.37
Immunoprecipitation and Immunoblotting
Cells or platelets were lysed in 50 mmol/L HEPES, pH
7.5, 150 mmol/L NaCl, 1.0% Triton X-100, 5.0 mmol/L
MgCl2, 1.0 mmol/L EGTA, 25 mg/mL leupeptin, 2.0 mmol/L
sodium orthovanadate (Na3VO4), 10 mg/mL pepstatin A, and
2.0 mmol/L phenylmethylsulfonyl fluoride. The lysates were
then cleared by centrifugation (14,000 rpm, 10 minutes).
Immunoprecipitation, SDS-PAGE, and immunoblotting anal-
ysis were performed as previously described.38 Antibodies
bound to polyvinylidene fluoride membranes were detected by
chemiluminescence with enhanced chemiluminescence (ECL;
Amersham Life Sciences, Little Chalfont, England).
Determination of Prostaglandin E2 Levels in
Cell Supernatants
Prostaglandin (PG) E2 levels in cell supernatants were
determined by a specific radioimmunoassay.39 PGE2 values
were expressed as picograms per 105 cells. All determinations
were performed in triplicate.
Statistical Analysis
Results, relative to the number of experiments indi-
cated, are expressed as mean 6 SD. Statistical analysis was
performed by one-way analysis of variance, and, when the F
value was significant, by Duncan’s test. Unless otherwise spec-
ified, P values of ,0.05 were considered statistically signifi-
cant.
Results
NO Donors Reduce PDGF-Induced Cell
Proliferation and Chemotaxis
The effects of increasing concentrations of NTG
and SNAP on PDGF-BB–induced DNA synthesis, mea-
sured as [3H]thymidine incorporation into DNA, were
first evaluated. The 2 NO donors used for this study are
characterized by different intracellular pharmacologic
dynamics leading to NO release. NO donors such as
SNAP release NO spontaneously, whereas NTG, a classic
organic nitrate, releases NO after enzymatic metabolism
involving conjugation with cysteine-rich residues in var-
ious cells including fibroblasts and smooth muscle
cells.40
As shown in Figure 1A, preincubation with both NO
donors for 10 minutes induced a dose-dependent inhibi-
tion of PDGF-induced mitogenesis. This inhibitory ef-
fect was statistically significant starting at 1 mmol/L.
The difference between the 2 compounds was statistically
significant only at 100 mmol/L, although SNAP tended
to be slightly more potent than NTG at any concentra-
tion tested. Growth curve experiments for activated hu-
man HSCs in response to PDGF-BB with or without NO
donors were performed to show whether the decrease in
PDGF-induced mitogenesis is associated with an actual
decrease in cell growth. As shown in Figure 1B,
PDGF-BB at a dose of 10 ng/mL significantly increased
HSC growth after 2 and 4 days of incubation compared
with unstimulated control cells (P , 0.001). This effect
was clearly reduced by pretreatment with both NTG and
SNAP, and this reduction was already statistically sig-
nificant after 2 days of culture. The effects of NO donors
were not associated with any cytotoxic effects in the dose
range used.
To provide evidence that the inhibitory effects of NO
donors on PDGF mitogenic potential were indeed caused
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by NO release, we performed [3H]thymidine incorpora-
tion experiments by incubating HSCs with 1026 mol/L
methylene blue, a well-known NO oxidizing agent,41
before the addition of NO donors. This treatment re-
sulted in a statistically significant reduction of the in-
hibitory effect of both NTG and SNAP, thus confirming
that their effects are actually caused by NO release (data
not shown).
In addition to their effects on PDGF-induced mitogen-
esis, both NTG and SNAP caused a dose-dependent reduc-
tion of PDGF-BB–induced chemotaxis in a modified Boy-
den chamber system (Figure 2). The inhibitory effect of
SNAP was more pronounced than that of NTG, with
statistically different potency at any concentration tested.
NO Donors Affect PDGF-Induced
Intracellular Signaling
The effects of NO donors on PDGF-induced sig-
naling were then evaluated. As shown in Figure 3, in
individual Fura-2–loaded human HSCs, stimulation
with PDGF (control) caused the occurrence of an earlier
synchronous Ca21 spike over an average basal [Ca21]i of
90–100 nmol/L, followed by a long-lasting plateau, as
Figure 2. Effect of NO donors on PDGF-induced cell migration in
activated human HSCs. Dose response for the effect of increasing
concentrations of NO donors on PDGF-induced cell migration. Cell
migration was measured by the Boyden chamber assay (see Materials
and Methods). Cells were seeded in SFIF medium in the upper com-
partment of the Boyden chamber and tested for migration in the lower
chamber through a filter precoated with collagen type I. Cells that had
migrated to the lower surface of the filter after 6 hours were stained
and visually quantitated by cell counting. The values (cells migrated
per high-power fields) are expressed as mean 6 SD and are from 8
separate fields counted in 3 different experiments. Compared with the
effect of PDGF-BB alone, changes were statistically significant (P ,
0.05 or higher degree of significance) starting at 1.0 mmol/L for both
NO donors.
Figure 1. Effect of NO donors on PDGF-induced cell proliferation in activated human HSCs. (A) Dose response for the effect of increasing
concentrations of NO donors on DNA synthesis, evaluated as [3H]thymidine incorporation into DNA, induced by PDGF-BB. Confluent cells in
24-well dishes were incubated for 48 hours in SFIF medium, then pretreated for 10 minutes with increasing concentrations of NO donors before
starting an incubation with 10 ng/mL PDGF-BB for a total of 24 hours. Cells were pulsed with [3H]thymidine during the last 4 hours of incubation.
Data are mean 6 SD for 4 experiments performed in triplicate. Compared with the effect of PDGF-BB alone, changes were statistically significant
(P , 0.05 or higher degree of significance) starting at 1.0 mmol/L for both NO donors. (B) Effect of NO donors on PDGF-BB–induced HSC
proliferation. Cells were plated in 12-well dishes at a density of 6 3 104 cells/well in complete culture medium. After 24 hours (day 0), cells were
washed twice with SFIF medium and then incubated in fresh SFIF medium alone (control) or containing 10 ng/mL PDGF-BB with or without
preincubation with NTG (50 mmol/L) or SNAP (10 mmol/L). At each time point (day 2 and day 4), cells were trypsinized and counted with a Coulter
cell counter. Fresh medium containing the same test conditions was added to the remaining wells at each time point. Data (mean 6 SD),
expressed as the absolute cell number, are from 2 experiments performed in triplicate. *P , 0.005 or higher degree of significance compared
with cells treated with NO donors.
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reported previously.34 Ten-minute preincubation with
either NTG (100 mmol/L) or SNAP (100 mmol/L) caused
a marked reduction of both the peak and the plateau
phase. Similar effects, although less marked, were ob-
served with a lower concentration of both NO donors (10
mmol/L; data not shown).
Exposure of serum-deprived human HSCs to
PDGF-BB resulted in ERK activation after 5 minutes of
incubation with a peak effect at 10 minutes (Figure 4A,
lanes 1 and 2). Preincubation with both NTG and SNAP
before the addition of PDGF-BB caused a dose-depen-
dent inhibition of ERK activity (Figure 4A, lanes 3–6).
Again, SNAP appeared more potent than NTG, with
complete abrogation of the PDGF-induced increase of
ERK activity at a dose of 10 mmol/L.
The effects of NO donors on PDGF signaling were
further detailed by evaluating their action on PDGF-
induced increase in c-fos gene expression as a downstream
target of ERK activation. As shown in Figure 4B, c-fos
messenger RNA (mRNA) expression, not detectable in
baseline conditions (lane 1), became clearly evident 30
minutes after the addition of PDGF (lane 2), and was
clearly reduced by cell preincubation with both SNAP
and NTG (lanes 3 and 4, respectively).
Effect of NO Donors on the Guanylate
Cyclase/cGMP System
The action of NO donors is known to be largely
dependent on the NO-induced activation of sGC, par-
ticularly of the heterodimeric form a1b1.42,43 Activation
of sGC leads to cGMP generation and to other down-
stream events including activation of protein kinase (PK)
G.44–47 To verify this hypothesis, the effects of NTG and
SNAP on the sGC/cGMP system were investigated. The
inhibitory effect of NTG (100 mmol/L) on PDGF-in-
duced DNA synthesis was evaluated in the presence of
LY-83583, an inhibitor of guanylyl cyclase activity, and
Figure 3. Effect of NO donors on PDGF-induced intracellular Ca21
increase in individual Fura-2–loaded activated human HSCs. Subcon-
fluent (70%–80% confluent) cells were maintained in SFIF medium for
48 hours and were then loaded with Fura-2–AM (see Materials and
Methods). PDGF-BB (10 ng/mL) was added (arrow, time 0). The
tracings show changes in [Ca21]i induced by PDGF without (control) or
with a 10-minute preincubation with 100 mmol/L NTG or 100 mmol/L
SNAP. Data are the mean of 25 determinations in individual cells
stimulated with PDGF compared with an identical number of cells
pretreated with NO donors. For each single point, SD did not exceed
15% of the mean value. Measurements were obtained at 3-second
time intervals.
Figure 4. Effect of NO donors on PDGF-induced ERK activity and c-fos
mRNA expression in activated human HSCs. (A) Confluent cells in
100-mm dishes were maintained for 48 hours in SFIF medium and
then pretreated with NTG (10 and 100 mmol/L; lanes 3 and 4,
respectively) or SNAP (5 and 10 mmol/L; lanes 5 and 6, respectively)
for 10 minutes before stimulation with PDGF-BB (10 ng/mL; lanes
2–6) for 10 minutes. ERK activity was analyzed as the ability of ERK
immunoprecipitates to phosphorylate myelin basic protein (MBP) (see
Materials and Methods). Control refers to cells incubated for 48 hours
in SFIF medium alone. Representative experiment of 3. (B) Confluent
cells in 100-mm dishes were maintained for 48 hours in SFIF medium
and then pretreated with SNAP (10 mmol/L; lane 3) or NTG (10
mmol/L; lane 4) for 10 minutes before stimulation with PDGF-BB (10
ng/mL; lanes 2–4) for 30 minutes. Control refers to RNA isolated
from cells incubated for 48 hours in SFIF medium alone. RNA purifi-
cation and hybridization were performed as detailed in Materials and
Methods. c-fos complementary DNA probe was then removed by
boiling, and the same blot was hybridized to a complementary DNA
encoding for the ribosomal protein 36B4 (control gene). Representa-
tive experiment of two.
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KT5823, an inhibitor of PKG activity. At the concen-
trations tested, both compounds are rather specific in
their action.48,49 However, as shown in Figure 5A, inhi-
bition of either guanylyl cyclase or PKG did not affect
the inhibitory effect of NTG. Identical results were
obtained when the action of both compounds was tested
on the inhibitory effect of SNAP and when a wider range
of concentrations was used in the same experiment (LY-
83583, 10211 to 1026 mol/L; KT5823, 0.05–2.0
mmol/L) (data not shown). At concentrations higher than
those indicated, both LY-83583 and KT5823 induced
further inhibition of DNA synthesis caused by cytotox-
icity. We next examined cGMP synthesis in response to
NO donors in our cell system. As shown in Figure 5B,
incubation of human HSCs with NTG and SNAP for 10
minutes, even at the maximal doses used, did not result
in cGMP synthesis over control values. Identical results
were obtained with shorter (1- and 5-minute) and longer
(15- and 30-minute) periods of incubation with NO
donors (data not shown). Because of these results, we
examined the expression of the a1b1 heterodimeric form
of sGC in protein extracts obtained from different lines of
activated human HSCs, including the 3 cell lines used in
our present experiments (HFSC3, HFSC6, and HFSC7)
by Western blot analysis. As shown in Figure 6A, a clear
band corresponding to the a1b1 heterodimeric form of
sGC was detected in protein extracts obtained from
human platelets (lane 1) included as a positive control,
whereas it was absent in all the preparations obtained
from activated human HSCs. To establish whether the
lack of expression of the a1b1 heterodimeric form of sGC
constitutes a peculiar feature on human HSCs in their
activated state, the expression of this protein was inves-
tigated in HSCs freshly isolated from normal human
liver and followed during their activation caused by serial
subculture on plastic. As shown in Figure 6B, in freshly
isolated HSCs (lane 2), expression of the a1b1 het-
erodimeric form of sGC was clearly evident, but became
undetectable after activation in culture (serial passages
1–3, split ratio 1:3, lanes 3–5, respectively). Accord-
ingly, NO donors, particularly SNAP, were able to in-
duce cGMP synthesis in freshly isolated HSCs (Figure
6C), whereas no increase was observed after activation in
culture (serial passage 1). Together, the results of these
experiments suggest that, in activated human HSCs, the
sGC/cGMP system does not represent a major effector of
the action of NO donors, at least in the dose range used.
In addition, the lack of expression of the ubiquitous a1b1
heterodimeric form of sGC may represent a distinct
feature of the process of human HSC activation and
phenotypical modulation.
Effect of NO Donors on PGE2 Synthesis
NO, either as a gaseous solution or as released by
an NO donor, has been shown to promote cyclooxygen-
ase (COX) activity and, consequently, PG synthesis.50
Therefore, we evaluated PGE2 release in HSC superna-
tants in response to NTG and SNAP. As shown in Figure
7, compared with a representative time-course experi-
ment performed using maximal doses of NO donors,
both compounds elicited a significant increase in PGE2
synthesis over control starting as soon as 2.5 minutes
after stimulation, and still present after 30 minutes. At
each time point tested, NTG was always remarkably
Figure 5. Effect of NO donors on the guanylate cyclase/cGMP system
in activated human HSCs. (A) Effect of LY-83583, an inhibitor of sGC
activity, and KT5823, an inhibitor of PKG, on the inhibitory action
exerted by NTG on PDGF-induced DNA synthesis, evaluated as [3H]thy-
midine incorporation into DNA. Experiments were conducted as indi-
cated in Figure 1A and in Materials and Methods. LY-83583 and
KT5823, at the concentrations indicated, were added 10 minutes
before starting the preincubation with NTG. (B) Effect of NO donors on
intracellular cGMP levels. Confluent cells were incubated in SFIF
medium for 48 hours and then stimulated with PDGF-BB (10 ng/mL)
or the indicated doses of NTG or SNAP for 10 minutes. Std-cGMP,
data relative to a standard concentration of cGMP (8 pmol), included
as a positive control for the assay. Radioimmunoassay procedures
were as described in Materials and Methods. Data, expressed as
picomoles per 105 cells, are the mean 6 SD of 4 experiments
performed in triplicate.
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more potent than SNAP in inducing PGE2 synthesis. In
addition, a 2-fold increase in PGE2 synthesis was also
observed after stimulation with PDGF-BB, thus con-
firming recently reported observations in this cell type.51
PGE2 Synthesis Blockade Abrogates the
Inhibitory Effect of NO Donors on
PDGF Action
Because the increase in PGE2 synthesis elicited by
NO donors could activate the adenylate cyclase/cAMP
pathway through specific receptors52 and cAMP affects
PDGF biological effects and intracellular signaling,52,53
experiments were repeated by evaluating DNA synthesis
and ERK activity in the presence of the COX inhibitor
ibuprofen. As shown in Figure 8A, pretreatment with
ibuprofen exerted a dose-related abrogation of the inhib-
itory effect of NO donors on PDGF-induced DNA syn-
thesis. In addition, pretreatment with ibuprofen signif-
icantly enhanced the mitogenic effect of PDGF, similar
to the data of Mallat et al.51 Accordingly, the observed
inhibition of PDGF-induced ERK activity exerted by
NTG and SNAP was completely abolished when cells
were preincubated with ibuprofen (Figure 8B). Finally,
to characterize the involvement of the adenylate cyclase/
cAMP pathway, we examined intracellular cAMP syn-
thesis in response to NO donors in the absence and
presence of ibuprofen. In these experiments, pentoxifyl-
line, a phosphodiesterase inhibitor, was included as a
positive control.53 As shown in Figure 8C, both NTG
Figure 7. Effect of PDGF-BB and NO donors on PGE2 synthesis in
activated human HSCs. Determination of PGE2 immunoreactivity in
cell culture supernatants. Confluent cells were incubated for 48 hours
in SFIF medium. Cells were then washed twice with the same medium
and incubated without (control) or with test conditions for the indi-
cated times. PGE2 was extracted from conditioned medium, and PGE2
immunoreactivity was determined as detailed in Materials and Meth-
ods. Data (pg/105 cells) are the mean 6 SD of 4 experiments
performed in triplicate. Compared with control conditions, all agonists
induced statistically significant changes (P , 0.05 or higher degree of
significance) in PGE2 synthesis starting at 2.5 minutes of incubation.
Figure 6. Activation of human HSCs is associated with down-regula-
tion of the a1b1 heterodimeric form of sGC. (A) Expression of sGC
a1–b1 subunits in different lines of activated human HSCs. Western
blot analysis of 50 mg of protein obtained from cell lysates separated
by 7.5% SDS-PAGE. Cell lysates were obtained from human platelets
(positive control; lane 1) and from 5 independent lines of human
HSCs (cell lines 8, 3, 11, 6, and 7; lanes 2–6) maintained in standard
culture conditions. 2P(number) refers to the serial passage of cul-
ture. Representative blot of 2. (B) Expression of sGC a1b1 subunits
during the process of human HSC activation. Western blot analysis of
50 mg of protein obtained from cell lysates separated by 7.5% SDS-
PAGE. Cell lysates were obtained from human platelets (positive
control; lane 1), from HSCs freshly isolated from normal liver (lane 2),
and from the same cell preparation after 3 serial passages in culture
(P1–P3; lanes 3–5, respectively). (C) Effect of NO donors on intracel-
lular cGMP levels in freshly isolated human HSCs and after the first
serial passage (passage 1). Freshly isolated cells were divided into
aliquots of 5 3 105/tube and resuspended in 1 mL of SFIF medium
containing 100 mmol/L IBMX. After 10 minutes of incubation at 37°C,
cells were stimulated with NTG or SNAP for 10 minutes. Experiments
on passage 1 cells were performed as described in Figure 5. Radio-
immunoassay procedures were as described in Materials and Meth-
ods. Data (pmol/105 cells) are the mean 6 SD of 3 experiments.
*P , 0.05 (or higher degree of significance) vs. unstimulated cells.
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and SNAP increased intracellular cAMP synthesis over
control values. NTG appeared to be significantly more
potent than SNAP. Preincubation with ibuprofen com-
pletely abrogated this effect, thus confirming that this
effect of NO donors was probably mediated by the
increase in PGE2 synthesis.
Effect of NO Donors on PDGF-Induced
PLC-g Phosphorylation
The effect of NO donors on PDGF-induced phos-
phorylation of PLC-g, a signaling molecule physically
associated with the PDGF receptor, was also evaluated.
This experimental approach was introduced to attempt
to explain the observed different order of potency of
SNAP vs. NTG on PDGF-induced biological effects and
signaling (i.e., SNAP always more potent than NTG)
and their effect on PGE2 and cAMP synthesis (i.e., NTG
always more potent than SNAP). Indeed, this discrep-
ancy argues against the assumption that the effect of both
NO donors is largely, if not exclusively, caused by in-
creased PGE2 synthesis. As shown in Figure 9A, NTG
did not modify the level of PLC-g phosphorylation after
stimulation with PDGF, whereas SNAP produced a
marked inhibition with complete abrogation of this ef-
fect at 10 mmol/L. Pretreatment with either NTG or
SNAP did not affect the levels of PDGF receptor phos-
phorylation after stimulation with the growth factor
(Figure 9B). These results suggest that, compared with
NTG, SNAP exerts at least this additional effect onP-
DGF signaling that is independent from PGE2 syn-
thesis.
Effect of NO Donors on Thrombin-Induced
[Ca21]i Increase and Cell Contraction
To provide further evidence supporting the action
on NO donors in the treatment of portal hypertension,
the effects of NTG and SNAP on thrombin-induced
[Ca21]i increase and contraction in activated human
HSCs were evaluated (Figure 10). As previously re-
ported,8 stimulation of HSCs with 0.3 U/mL of human
thrombin resulted in increased [Ca21]i coupled with a
simultaneous and transient reduction of cell area, indi-
cating reversible cell contraction. Preincubation with
100 mmol/L of NTG resulted in a very marked reduction
of the [Ca21]i increase and in a complete abrogation of
cell contraction. Identical results were obtained by pre-
incubating the cells with 100 mmol/L of SNAP (data not
shown).
Figure 8. Blockade of PGE2 synthesis eliminates inhibitory effects of
NO donors. (A) Effect of ibuprofen (IBPF), an inhibitor of COX activity, on
the inhibitory action exerted by NTG and SNAP on PDGF-induced DNA
synthesis, evaluated as [3H]thymidine incorporation into DNA. Exper-
iments were conducted as in Figure 1A and in Materials and Methods.
Ibuprofen, at the concentrations indicated, was added 10 minutes
before starting the preincubation with NO donors. (B) Effect of ibupro-
fen (IBU) on the inhibitory action exerted by NTG and SNAP on PDGF-
induced ERK activity. Experiments were conducted as in Figure 3 and
in Materials and Methods. Ibuprofen (1026 mol/L) was added 10
minutes before starting the preincubation with NO donors. Control,
cells incubated for 48 hours in SFIF medium alone. MBP, myelin basic
protein. Representative experiment of 2. (C) Effect of NO donors on
intracellular cAMP levels in the presence or absence of ibuprofen.
Confluent cells were incubated in SFIF medium for 48 hours and then
stimulated with NTG or SNAP for 10 minutes. Ibuprofen (25 3 1026
mol/L) was added 10 minutes before stimulation with NO donors.
Control, cells incubated for 48 hours in SFIF medium alone. Stimula-
tion with pentoxifylline (170 mmol/L) was included as a positive
experimental control. Data (fmol/105 cells) are the mean 6 SD of 2
experiments performed in triplicate. *P , 0.05 (or higher degree of
significance) vs. the same condition without ibuprofen.
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Discussion
The results of this study indicate that NO donors
belonging to different pharmacologic classes (organic
nitrates and S-nitrosothiols) are able to negatively mod-
ulate two key biological effects of PDGF in fully acti-
vated human HSCs (cell proliferation and chemotaxis), as
well as the activation of PDGF-induced intracellular
signaling pathways. These effects of NO donors are pre-
dominantly exerted through mechanisms that are alter-
native to the classic sGC/cGMP pathway caused by the
lack of sGC expression, occurring during the process of
HSC activation and phenotypical modulation.
The action of NO donors has been shown to be largely
dependent on activation of the sGC/cGMP pathway in
most cell types,41,42 including rat stellate cells.54 There-
fore, the involvement of this system in the inhibitory
effect of NO donors on PDGF-induced effects and sig-
naling in human HSCs was first evaluated. NO causes
activation of sGC, particularly of the heterodimeric form
a1b1. cGMP generation then leads to other signaling
events, including activation of PKG.44–47 Several lines of
evidence, obtained in vascular smooth muscle cells, in-
dicate that the activation of this pathway could directly
affect PDGF intracellular signaling at different lev-
els.55–58 According to this working hypothesis, inhibi-
tion of cGMP synthesis and/or of PKG activity should
cause a reduction, if not the abrogation, of the inhibitory
effect exerted by NO donors on PDGF-induced DNA
synthesis. This dual strategy was motivated by recent
experimental evidence indicating that inhibition of PKG
activity may not be sufficient to abrogate cGMP-depen-
Figure 9. Effect of NO donors on PLCg phosphorylation in activated
human HSCs. (A) Confluent cells were incubated for 48 hours in SFIF
medium. Cells were then pretreated with the indicated doses of NO
donors for 10 minutes before stimulation with PDGF-BB (10 ng/mL)
for 10 minutes. Equal amounts of proteins were immunoprecipitated
using an anti-PLCg antibody. The immunoprecipitates were analyzed
by SDS-PAGE (7.5%), followed by immunoblotting with antiphosphoty-
rosine (PY) antibody (See Materials and Methods). Control, cells incu-
bated for 48 hours in SFIF medium alone. Representative experiment
of 3. (B) Confluent cells were incubated for 48 hours in SFIF medium.
Cells were then pretreated with the indicated doses of NO donors for
10 minutes before stimulation with PDGF-BB (10 ng/mL) for 10
minutes. Equal amounts of proteins were immunoprecipitated using
an anti–PDGF receptor (R) b subunit antibody. The immunoprecipi-
tates were analyzed by SDS-PAGE (7.5%), followed by immunoblotting
with antiphosphotyrosine (PY) antibody (see Materials and Methods).
Representative experiment of 2. In A and B, control refers to cells
incubated for 48 hours in SFIF medium alone.
Figure 10. Effect of NTG on thrombin-induced [Ca21]i increase and
cell contraction. Effect of thrombin (THR, 0.3 U/mL, arrow) on [Ca21]i
(nmol/L, closed symbols, left vertical axis) and cell area (mm2, open
symbols, right vertical area) in a single Fura-2–loaded human HSC in
(A) control condition and (B) after preincubation with 100 mmol/L
NTG. Time courses represent typical examples of the thrombin effect.
Horizontal axis indicates time in seconds.
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dent effects of NO.29,59 Both procedures did not result in
evident changes in the inhibitory effects exerted by both
NTG and SNAP. This discrepancy with the working
hypothesis was initially ascribed to a possible lack of
specificity of both LY-83583 and KT5823, although
they were used according to the modalities and dosages
reported in the literature.48,49 However, showing that
stimulation with NO donors does not result in increased
cGMP levels confirmed the possibility of an impairment
of this system in activated human HSCs. To gain further
insight, the expression of the heterodimeric form a1b1 of
sGC was analyzed in different cell lines of activated
human HSCs. The heterodimeric form a1b1 is referred to
as ubiquitous and represents a specific target for NO: the
enzyme contains heme as a prosthetic group, and NO, in
binding to the heme moiety, causes a marked activation
of the enzyme.60,61 The observation that the expression of
the heterodimeric form a1b1 of sGC is not detected in
activated human HSCs raises the possibility of a down-
regulation of this enzyme, as suggested for other patho-
physiologic conditions.42 At the cellular level, prolonged
pretreatment with mediators such as interleukin 1b and
lipopolysaccharide causes a marked inhibition of sodium
nitroprusside–induced activation of sGC.62 In addition,
an endogenous inhibitor of sGC has been identified and
partially purified from bovine lung.63 Because the lack of
detectable expression of the heterodimeric form a1b1 of
sGC is common to HSC lines isolated from normal liver
tissue obtained from different individuals and activated
by culture on plastic, it is tempting to speculate that this
represents a general feature related to the process of HSC
activation in which several structural and functional
changes occur, including the establishment of autocrine
loops for growth factors, cytokines, and other soluble
mediators.11,12 This possibility is consistent with the
finding that expression of the heterodimeric form a1b1
of sGC and NO donor–induced cGMP synthesis are
evident in quiescent HSCs, freshly isolated from normal
human liver, whereas they become undetectable during
serial subculture on plastic.
The inability of NO donors to induce cGMP accumu-
lation in fully activated human HSCs is in contrast with
previous reports in stellate cells isolated from rat liver,54
in which sodium nitroprusside at rather high doses (500
mmol/L) was shown to increase intracellular cGMP lev-
els. This discrepancy could be caused by the fact that rat
stellate cells were used in an earlier stage of activation,
although species differences between rat and human cells
cannot be ruled out.
The role of NO in the regulation of COX activity and
its importance in physiology, pathology, and therapy has
been highlighted in recent years.50,64–66 Evidence from
several studies suggests that COX enzymes are targets for
the pathophysiologic roles of NO and that, once acti-
vated in the presence of NO, they represent important
transduction mechanisms for its multifaceted actions.
The pathway leading to COX activation by NO is still
poorly elucidated but, analogously to sGC, may involve
an interaction with the iron-heme center of the en-
zyme.50 The data in our present study suggest that
incubation with NO donors results in a rapid and sus-
tained increase in PGE2 synthesis in activated human
HSCs. In agreement with this observation, it is possible
that the inhibitory action of NO donors on PDGF action
and signaling is mediated through an autocrine loop
involving PGE2: these autacoids, by interacting with the
specific membrane receptor, activate the adenylate cy-
clase/cAMP/PKA. Along these lines, established experi-
mental evidence obtained in activated human HSCs has
clearly shown that activation of this signaling pathway is
associated with effects on PDGF action and signaling
similar to those observed in the presence of NO do-
nors.51–53 In agreement with this alternative working
hypothesis, PGE2 synthesis blockade obtained by using
the COX inhibitor ibuprofen results in a decrease in NO
donor–induced cAMP synthesis and in abrogation of the
inhibitory effect of NO donors on both PDGF action and
intracellular signaling.
These results suggest that the pharmacologic effects of
NO donors in activated human HSCs are largely depen-
dent on the activation of the adenylate cyclase/cAMP/
PKA pathway. However, in comparing the effects of the
compounds used as tools to deliver intracellular NO in
human HSCs, NTG, and SNAP, it is clear that the
relative mechanisms of action may be, at least in part,
different. Although SNAP always appears more potent
than NTG in inhibiting PDGF biological effects and
intracellular signaling, its effect on PGE2 and cAMP
synthesis is significantly lower in comparison with NTG.
It is therefore conceivable that the action of SNAP is
partially independent of the activation of the adenylate
cyclase/cAMP/PKA pathway. In particular, considering
the effect of NO donors on PDGF-induced [Ca21]i in-
crease, it is evident that SNAP exerts a more pronounced
inhibitory action when compared with NTG. According
to the available knowledge, activation of the cAMP/PKA
pathway may cause phosphorylation of both membrane
and sarcoendoplasmic reticulum calcium ATPases in sev-
eral cell types, including smooth muscle cells. Phosphor-
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ylation is associated with increased activity of these
calcium pumps with a consequent increase in the velocity
of cytosolic calcium resetting to prestimulatory values
after calcium transient.67 The results of the present study
suggest that, in addition to this mechanism, pretreat-
ment with SNAP may influence PDGF-induced [Ca21]i
increase through a dose-dependent inhibition of PDGF-
induced PLCg phosphorylation, and possibly its activa-
tion with reduced synthesis of downstream effectors,
such as IP3, is able to affect [Ca21]i dynamics. This
observation is similar to previous findings in fibroblasts
where inhibition of PLCg phosphorylation was shown to
be a possible molecular target for the action of NO.55
Demonstration of an inhibitory effect of NO donors on
PDGF-induced biological effects in human HSCs sug-
gests that these therapeutic agents may exert a direct
antifibrogenic action by inhibiting proliferation, motil-
ity, and contractility of this key cell type, in addition to
a reduction of fibrillar extracellular matrix accumulation.
Accordingly, prolonged administration of orally active
NO donors may reduce the contractility of HSCs present
in fibrotic septa as well as their proliferation, migration,
and extracellular matrix accumulation, thus affecting
several mechanisms responsible for the increased intra-
hepatic resistance to portal flow. Although oral admin-
istration of nitrovasodilators, NTG in particular, may
result in active concentrations within the portal circula-
tion fairly close to those used in the present study,68 the
introduction of orally active NO donors, reaching higher
concentrations within the portal circulation and provided
with better intrahepatic bioavailability, may further im-
prove the treatment of portal hypertension caused by
fibrogenic chronic liver diseases.
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